• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » FDA reviews adverse events, durability of Inspire Medical’s sleep apnea implant

FDA reviews adverse events, durability of Inspire Medical’s sleep apnea implant

February 19, 2014 By Arezu Sarvestani

Inspire Medical's sleep apnea implant heads to the FDA

Minnesota-based Inspire Medical Systems has a date with the FDA tomorrow, when the agency’s expert Anesthesiology & Respiratory Therapy Devices Panel will review data and make a recommendation on the Inspire II Upper Airway Stimulator.

Inspire Medical was spun out of medtech titan Medtronic (NYSE:MDT) in 2007, taking with it therapy concepts stemming from trials begun in 1998. The company’s Inspire II device is a permanent implant designed to stimulate nerves to keep the airways open during sleep. The implant delivers mild electrical stimulation to the hypoglossal nerve, preventing the tongue from obstructing breathing.

Inspire Medical won CE Mark approval in 2010 to market the device in the European Union.

In materials released ahead of tomorrow’s panel review, FDA regulators highlighted concerns with non-serious adverse events associated with long-term use of the implant and asked its advisors to consider the durability of the therapy, proper screening methods, post-approval study protocols and other aspects of the technology and its potential entry to the U.S. market.

In a draft of questions for the panel, the FDA asks reviewers to dig into the adverse events seen during Inspire’s clinical trials, including cases of tongue soreness, irritation and abrasion, mouth dryness, mechanical pain and discomfort associated with electrical stimulation. Some of the adverse events remained unresolved by the end of the trial, regulators noted. Inspire had recommended a 12-month follow-up study to watch for specific adverse events, but the FDA’s review team is leaning toward 5 years since the device is a permanent implant and adverse events seen in trials were long-lasting, the agency said.

The FDA further asked the panel to consider that some patients in the clinical trials underwent several titrations or fine-tuning of their stimulators to address discomfort. Given the need for multiple titrations, the FDA asked reviewers to consider whether the trial had a meaningful thread of time to demonstrate durability in treatment and how best to address potential tuning needs in the device’s label.

Tomorrow’s panel will also address patient screening methods to determine which are best candidates for the therapy as well as trial parameters and protocols for post-approval studies. The reviewers will meet tomorrow from 8 a.m. to 6 p.m.

UPDATE: FDA panel recommends Inspire Medical’s sleep apnea implant

Filed Under: Food & Drug Administration (FDA), Neuromodulation/Neurostimulation, News Well, Pre-Market Approval (PMA), Regulatory/Compliance Tagged With: Inspire Medical Systems Inc., Minnesota, Sleep Monitoring/Sleep Apnea

More recent news

  • EBR Systems raises $36.1M for leadless pacing tech
  • The biggest cardiovascular tech news out of EuroPCR 2025
  • CardiaWave has positive 12-month Valvosoft results
  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Medtronic has new Cardiovascular, CST leaders after longtime exec departs

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy